广济药业(000952) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit loss of between 270 million and 299 million yuan for the year 2024, a decline of 92.52% to 113.19% compared to the previous year's loss of 140.25 million yuan[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 284 million and 313 million yuan, representing a decrease of 94.14% to 113.96% from the previous year's loss of 146.29 million yuan[2]. - Basic earnings per share are expected to be a loss of between 0.7717 yuan and 0.8546 yuan, compared to a loss of 0.3962 yuan per share in the previous year[2]. - Operating revenue is anticipated to be between 620 million and 650 million yuan, down from 737.82 million yuan in the previous year[2]. Factors Affecting Performance - The company attributes the performance decline to intensified competition in the vitamin market, leading to decreased sales of its main product, vitamin B2, and a drop in gross profit[4]. - Production capacity at the Jining facility has not been fully utilized, resulting in higher production costs and lower-than-expected sales prices, contributing to losses[4]. - Investment income has decreased compared to the previous year, primarily due to a reduction in non-recurring gains from affiliated units[5]. - Increased financing scale has led to higher interest expenses on related borrowings[5]. Caution and Disclosure - The company emphasizes that the performance forecast is based on preliminary estimates and the final financial data will be disclosed in the 2024 annual report[6]. - Investors are advised to exercise caution and be aware of investment risks as the company commits to timely information disclosure[6].